Glioma, Malignant Clinical Trial
Official title:
Concurrent Fluorescence and Sonographically Guided Eradication of Gliomas and Metastases Enhancing Contrast Agent in Magnetic Resonance Imaging: a Randomised, Controlled Trial
Objective of the study is to determine whether combined use of intraoperative fluorescence with 5-aminolevulinic acid (5-ALA) and sonography can achieve higher rate of gross total resection of contrast-enhancing gliomas and brain metastases compared to intraoperative fluorescence with 5-ALA alone.
Fluorescence-guided resection of contrast-enhancing gliomas and metastases increases extent of tumor resection. But the main drawback of this method is an inability to observe tumor fluorescence while it is covered with normal brain. Ultrasound can resolve this problem, allowing to reveal such tumor remnants. By the time there are published results of randomized control trials comparing these two technics. Objective of the study is to determine whether combined use of intraoperative fluorescence with 5-aminolevulinic acid (5-ALA) and sonography can achieve higher rate of gross total resection of contrast-enhancing gliomas and brain metastases compared to intraoperative fluorescence with 5-ALA alone. Participants of the study will be randomly operated using both fluorescence with 5-ALA and intraoperative ultrasound versus fluorescence with 5-ALA alone. Extent of resection will be assessed in postoperative MRI by blinded radiologists. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05557240 -
Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients
|
N/A | |
| Recruiting |
NCT05485038 -
General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas
|
N/A | |
| Active, not recruiting |
NCT04547621 -
HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05076513 -
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
|
Early Phase 1 | |
| Completed |
NCT05806619 -
Glioma: Biomolecular Aspects
|
||
| Not yet recruiting |
NCT04562077 -
Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
|
||
| Recruiting |
NCT06038760 -
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
|
||
| Completed |
NCT04497142 -
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05656053 -
Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging
|
||
| Recruiting |
NCT06196918 -
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
|
N/A | |
| Recruiting |
NCT05556486 -
Mapping of Tumor Stem Cells in the Resection Marigin During Extirpation of Highly Malignant Gliomas Using GlioStem
|
||
| Recruiting |
NCT05406700 -
Niraparib In Recurrent IDH 1/2 Gliomas
|
Early Phase 1 | |
| Recruiting |
NCT05773326 -
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
|
Early Phase 1 | |
| Active, not recruiting |
NCT05063682 -
The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients
|
Phase 1 | |
| Completed |
NCT05100173 -
Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients
|
||
| Completed |
NCT05100602 -
Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients
|
||
| Recruiting |
NCT05182905 -
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
|
Early Phase 1 | |
| Recruiting |
NCT06381726 -
Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life
|
N/A | |
| Completed |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 |